Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director · PRESIDENT AND CEO | October 06, 2026 | October 08, 2026 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | May 25, 2021 | May 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 767,780 |
Ending reported balance
After 2026-10-08 transaction · row 15
15 source rows · reconciled sequenceRow 1 · 2026-10-06 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 2 · 2026-10-06 · Sale · Disposed 2,300 · Balance 785,480 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-10-06 · Sale · Disposed 6,000 · Balance 779,480 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-10-06 · Sale · Disposed 9,920 · Balance 769,560 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-10-06 · Sale · Disposed 1,780 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-10-07 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 7 · 2026-10-07 · Sale · Disposed 8,600 · Balance 779,180 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-10-07 · Sale · Disposed 10,300 · Balance 768,880 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 9 · 2026-10-07 · Sale · Disposed 900 · Balance 767,980 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 10 · 2026-10-07 · Sale · Disposed 200 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 11 · 2026-10-08 · Exercise / conversion · Acquired 20,000 · Balance 787,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. Row 12 · 2026-10-08 · Sale · Disposed 4,810 · Balance 782,970 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F10: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 13 · 2026-10-08 · Sale · Disposed 3,090 · Balance 779,880 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F11: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 14 · 2026-10-08 · Sale · Disposed 11,900 · Balance 767,980 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F12: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 15 · 2026-10-08 · Sale · Disposed 200 · Balance 767,780 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 61,552 |
Reported balance
After 2026-10-06 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-10-06 · Exercise / conversion · Disposed 20,000 · Balance 61,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 41,552 |
Reported balance
After 2026-10-07 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-10-07 · Exercise / conversion · Disposed 20,000 · Balance 41,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2028-02-14 | Direct | 21,552 |
Reported balance
After 2026-10-08 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2026-10-08 · Exercise / conversion · Disposed 20,000 · Balance 21,552 F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028. F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on December 3, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2028.
F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.290. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.530 to $109.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.530 to $110.510. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.530 to $111.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: Represents a weighted average sales price per share. The shares were sold at prices ranging from $110.360 to $111.350. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: Represents a weighted average sales price per share. The shares were sold at prices ranging from $111.380 to $112.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: Represents a weighted average sales price per share. The shares were sold at prices ranging from $112.400 to $113.190. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: Represents a weighted average sales price per share. The shares were sold at prices ranging from $113.590 to $113.860. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F10: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.480 to $108.475. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F11: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.480 to $109.470. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F12: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.510 to $110.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F13: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 14, 2018.
QUEST DIAGNOSTICS INC
Report date May 25, 2021 · Filed May 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,260 |
Reported balance
After 2021-05-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-05-25 · Grant · Acquired 1,363 · Balance 6,260 F1: Represents an award of restricted share units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an award of restricted share units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2026 Filed Mar 4, 2026 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $12.07 | $120,700.00 |
DisclosureSEC source: 0001159036-26-000032 · wk-form4_1772668573.xml · nonDerivative · entry 8 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 777,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $12.07 Strike: $12.07 | $241,400.00 |
DisclosureSEC source: 0001159036-26-000032 · wk-form4_1772668573.xml · derivative · entry 12 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,923 Underlying: Common Stock · 20,000 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F9 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 6,519 | $69.33 | $451,981.83 |
DisclosureSEC source: 0001159036-26-000032 · wk-form4_1772668573.xml · nonDerivative · entry 7 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 767,780 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F6 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.220 to $69.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 13,481 | $68.85 | $928,166.85 |
DisclosureSEC source: 0001159036-26-000032 · wk-form4_1772668573.xml · nonDerivative · entry 6 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 774,299 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F5 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.220 to $69.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $12.07 | $241,400.00 |
DisclosureSEC source: 0001159036-26-000032 · wk-form4_1772668573.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 787,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $12.07 Strike: $12.07 | $241,400.00 |
DisclosureSEC source: 0001159036-26-000032 · wk-form4_1772668573.xml · derivative · entry 11 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 181,923 Underlying: Common Stock · 20,000 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F9 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 578 | $70.46 | $40,726.46 |
DisclosureSEC source: 0001159036-26-000032 · wk-form4_1772668573.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 767,780 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.380 to $70.620. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 15,322 | $69.80 | $1,069,460.28 |
DisclosureSEC source: 0001159036-26-000032 · wk-form4_1772668573.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 768,358 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.380 to $70.340. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,100 | $69.20 | $283,707.70 |
DisclosureSEC source: 0001159036-26-000032 · wk-form4_1772668573.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 783,680 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.375 to $69.370. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 23:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $12.07 | $241,400.00 |
DisclosureSEC source: 0001159036-26-000032 · wk-form4_1772668573.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 787,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 22,436 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000028 · wk-form4_1771974762.xml · derivative · entry 6 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,872 Underlying: Common Stock · 22,436 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 12,104 | $70.64 | $855,026.56 |
DisclosureSEC source: 0001159036-26-000028 · wk-form4_1771974762.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 767,780 F2 · shares: The reported disposition of 12,104 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 23, 2026 Filed Feb 24, 2026 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 22,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000028 · wk-form4_1771974762.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 779,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 16,757 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000028 · wk-form4_1771974762.xml · derivative · entry 5 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,270 Underlying: Common Stock · 16,757 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 9,040 | $70.98 | $641,659.20 |
DisclosureSEC source: 0001159036-26-000028 · wk-form4_1771974762.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 757,448 F1 · shares: The reported disposition of 9,040 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:12 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 16,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000028 · wk-form4_1771974762.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 766,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionPerformance Stock Units · Derivative | 51,171 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000025 · wk-form4_1771372286.xml · derivative · entry 9 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 51,171 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. F5 · derivative.expiration_date: This transaction represents the vesting and settlement of performance stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 16,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000025 · wk-form4_1771372286.xml · derivative · entry 8 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,874 Underlying: Common Stock · 16,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 21,009 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000025 · wk-form4_1771372286.xml · derivative · entry 7 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,009 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 27,605 | $79.44 | $2,192,941.20 |
DisclosureSEC source: 0001159036-26-000025 · wk-form4_1771372286.xml · nonDerivative · entry 6 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 749,731 F3 · shares: The reported disposition of 27,605 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 51,171 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000025 · wk-form4_1771372286.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 777,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 9,104 | $79.44 | $723,221.76 |
DisclosureSEC source: 0001159036-26-000025 · wk-form4_1771372286.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 726,165 F2 · shares: The reported disposition of 9,104 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 16,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000025 · wk-form4_1771372286.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,269 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 11,334 | $79.44 | $900,372.96 |
DisclosureSEC source: 0001159036-26-000025 · wk-form4_1771372286.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 718,394 F1 · shares: The reported disposition of 11,334 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2026 Filed Feb 17, 2026 23:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 21,009 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000025 · wk-form4_1771372286.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 729,728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 01:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 92,714 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000014 · wk-form4_1770861390.xml · derivative · entry 5 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,714 Underlying: Common Stock · 92,714 shares Expires not disclosed F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 20, 2025 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 01:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 24,985 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000014 · wk-form4_1770861390.xml · derivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,400 Underlying: Common Stock · 24,985 shares Expires not disclosed F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 23, 2024 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 01:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 19,807 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000014 · wk-form4_1770861390.xml · derivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,171 Underlying: Common Stock · 19,807 shares Expires not disclosed F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The Issuer awarded the reporting person performance-based vesting stock units ("PSUs") on February 16, 2023 that included a performance measurement period ending December 31, 2025. This transaction represents the Issuer's determination of the number of stock units that became eligible to vest based on performance for such performance period. The stock units remain subject to a service-based requirement through the third anniversary of the PSU grant date. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 01:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 50,013 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000014 · wk-form4_1770861390.xml · derivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,013 Underlying: Common Stock · 50,013 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 09, 2026 Filed Feb 12, 2026 01:56 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 53,847 | $0.00 Strike: $80.48 | $0.00 |
DisclosureSEC source: 0001159036-26-000014 · wk-form4_1770861390.xml · derivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,847 Underlying: Common Stock · 53,847 shares Expires 2036-02-09 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $12.07 Strike: $12.07 | $120,700.00 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · derivative · entry 13 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,923 Underlying: Common Stock · 10,000 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F9 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,624 | $78.94 | $365,000.06 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · nonDerivative · entry 10 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 708,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F8 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $78.643 to $79.292. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 5,376 | $78.38 | $421,365.50 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · nonDerivative · entry 9 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 713,343 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F7 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $77.640 to $78.637. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $12.07 | $120,700.00 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · nonDerivative · entry 8 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 718,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $12.07 Strike: $12.07 | $241,400.00 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · derivative · entry 12 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 211,923 Underlying: Common Stock · 20,000 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F9 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,100 | $77.54 | $783,154.00 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · nonDerivative · entry 7 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 708,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F6 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $77.290 to $77.990. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 9,900 | $76.94 | $761,666.40 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · nonDerivative · entry 6 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 718,819 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F5 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.275 to $77.260. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $12.07 | $241,400.00 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 728,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 20,000 | $12.07 Strike: $12.07 | $241,400.00 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · derivative · entry 11 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,923 Underlying: Common Stock · 20,000 shares Expires 2027-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F9 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 7,790 | $76.73 | $597,757.86 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 708,719 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $76.490 to $77.030. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 9,659 | $75.94 | $733,543.10 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 716,509 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $75.470 to $76.460. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 2,551 | $74.88 | $191,016.33 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 726,168 F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $74.450 to $75.442. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2026 Filed Feb 6, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 20,000 | $12.07 | $241,400.00 |
DisclosureSEC source: 0001159036-26-000012 · wk-form4_1770338320.xml · nonDerivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 728,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027. Read SEC document |
| December 09, 2025 Filed Dec 11, 2025 23:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantPerformance Stock Units · Derivative | 165,522 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001159036-25-000073 · wk-form4_1765494963.xml · derivative · entry 1 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,522 Underlying: Common Stock · 165,522 shares Expires not disclosed F1 · shares: Represents the grant of performance-based vesting Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of HALO common stock. The target number of Restricted Stock Units subject to the award is indicated. Up to two hundred percent (200%) of the target Restricted Stock Units could vest if the average closing price of HALO common stock over a period of 20 consecutive trading days during a four-year performance period following the grant of the award equals or exceeds certain price levels specified in the award (with 50% of target number of units vesting at $115 and an additional 50% of the target number of units vesting at each of $130, $145 and $170) and, in each case, only if the Reporting Person remains employed with the Registrant through the end of the performance period (subject to certain exceptions provided in the applicable award agreement). F1 · derivative.exercise_date: Represents the grant of performance-based vesting Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of HALO common stock. The target number of Restricted Stock Units subject to the award is indicated. Up to two hundred percent (200%) of the target Restricted Stock Units could vest if the average closing price of HALO common stock over a period of 20 consecutive trading days during a four-year performance period following the grant of the award equals or exceeds certain price levels specified in the award (with 50% of target number of units vesting at $115 and an additional 50% of the target number of units vesting at each of $130, $145 and $170) and, in each case, only if the Reporting Person remains employed with the Registrant through the end of the performance period (subject to certain exceptions provided in the applicable award agreement). F1 · derivative.expiration_date: Represents the grant of performance-based vesting Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of HALO common stock. The target number of Restricted Stock Units subject to the award is indicated. Up to two hundred percent (200%) of the target Restricted Stock Units could vest if the average closing price of HALO common stock over a period of 20 consecutive trading days during a four-year performance period following the grant of the award equals or exceeds certain price levels specified in the award (with 50% of target number of units vesting at $115 and an additional 50% of the target number of units vesting at each of $130, $145 and $170) and, in each case, only if the Reporting Person remains employed with the Registrant through the end of the performance period (subject to certain exceptions provided in the applicable award agreement). Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 00:31 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 16,569 | $8.11 Strike: $8.11 | $134,374.59 |
DisclosureSEC source: 0001159036-25-000063 · wk-form4_1764635501.xml · derivative · entry 7 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,569 shares Expires 2026-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F6 · derivative.exercise_date: Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 3, 2016. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 00:31 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 261 | $71.60 | $18,687.60 |
DisclosureSEC source: 0001159036-25-000063 · wk-form4_1764635501.xml · nonDerivative · entry 6 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 708,719 F2 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 00:31 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 500 | $70.36 | $35,181.00 |
DisclosureSEC source: 0001159036-25-000063 · wk-form4_1764635501.xml · nonDerivative · entry 5 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 708,980 F2 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F5 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.160 to $70.500. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 00:31 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 5,402 | $69.44 | $375,120.28 |
DisclosureSEC source: 0001159036-25-000063 · wk-form4_1764635501.xml · nonDerivative · entry 4 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 709,480 F2 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.160 to $70.100. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 00:31 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,406 | $68.51 | $712,935.87 |
DisclosureSEC source: 0001159036-25-000063 · wk-form4_1764635501.xml · nonDerivative · entry 3 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 714,882 F2 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.100 to $69.080. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 00:31 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 16,569 | $8.11 | $134,374.59 |
DisclosureSEC source: 0001159036-25-000063 · wk-form4_1764635501.xml · nonDerivative · entry 2 Torley Helen · CIK 0001528185 · Director · PRESIDENT AND CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 725,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in less than one year in February 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.